Cargando…

Effect of Sodium-Glucose Co-transporter Protein 2 Inhibitors on Arrhythmia in Heart Failure Patients With or Without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials

AIM: Arrhythmic events such as atrial fibrillation (AF) are tightly associated with an increased risk of heart failure (HF). Previous studies have shown inconsistent results regarding the association between sodium-glucose co-transporter 2 inhibitors (SGLT2i) and the risk of arrhythmia. The purpose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Ziwei, Zheng, Huizhen, Guo, Zhihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157597/ https://www.ncbi.nlm.nih.gov/pubmed/35665272 http://dx.doi.org/10.3389/fcvm.2022.902923

Ejemplares similares

Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure
por: Zeng, Qingchun, et al.
Publicado: (2021)

New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
por: Li, Juexing, et al.
Publicado: (2022)

Clinical benefit of sodium-glucose transport protein-2 inhibitors in patients with heart failure: An updated meta-analysis and trial sequential analysis
por: Chen, Xiehui, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey
por: Cappetta, Donato, et al.
Publicado: (2021)

The potential of sodium-glucose cotransporter 2 inhibitors for the treatment of systemic right ventricular failure in adults with congenital heart disease
por: Neijenhuis, Ralph M. L., et al.
Publicado: (2023)

Scientific evidence of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction: an umbrella review of systematic reviews and meta-analyses
por: Li, Runmin, et al.
Publicado: (2023)

Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
por: Mascolo, Annamaria, et al.
Publicado: (2022)

Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
por: Zhou, Hufang, et al.
Publicado: (2022)

The Efficacy and Safety of the Combined Therapy of Sodium-Glucose Co-Transporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitor in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Sub-Analysis
por: Lin, Yanxia, et al.
Publicado: (2022)

Cardiovascular outcomes in patients treated with sodium-glucose transport protein 2 inhibitors, a network meta-analysis of randomized trials
por: Tornyos, Dániel, et al.
Publicado: (2022)

Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis
por: Treewaree, Sukrit, et al.
Publicado: (2023)

Benefits of SGLT2 inhibitors in arrhythmias
por: Gao, Jinghan, et al.
Publicado: (2022)

Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials
por: Cheema, Huzaifa Ahmad, et al.
Publicado: (2023)

Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure
por: Kao, Ting-Wei, et al.
Publicado: (2022)

Triglyceride–Glucose Index and Extracellular Volume Fraction in Patients With Heart Failure
por: Yang, Shaomin, et al.
Publicado: (2021)

The Genetics and Epigenetics of Ventricular Arrhythmias in Patients Without Structural Heart Disease
por: Wang, Mengru, et al.
Publicado: (2022)

Sodium-glucose co-transporter-2 inhibitors reduce the risk of new-onset stroke in patients with type 2 diabetes: A population-based cohort study
por: Lin, Tsung-Kun, et al.
Publicado: (2022)

Case report: An unusual case of desmin myopathy associated with heart failure and arrhythmia
por: Liu, Xuhan, et al.
Publicado: (2022)

Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: A mini review
por: Wu, Jinchun, et al.
Publicado: (2022)

Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials
por: Tsai, Wan-Chuan, et al.
Publicado: (2022)

Sodium-Glucose Co-transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia/Reperfusion Injury by Limiting NLRP3 Inflammasome Activation and Modulating Autophagy
por: Yu, Yong-Wei, et al.
Publicado: (2022)

The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure
por: Fadiran, Olusayo, et al.
Publicado: (2021)

Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure
por: Li, Xuan, et al.
Publicado: (2022)

Corrigendum: Case report: An unusual case of desmin myopathy associated with heart failure and arrhythmia
por: Liu, Xuhan, et al.
Publicado: (2022)

Risk of hypovolemia associated with sodium–glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials
por: Rong, Xi, et al.
Publicado: (2022)

Ablation of Outflow Tract Arrhythmias in Patients With and Without Structural Heart Disease—A Comparative Analysis
por: Schleberger, Ruben, et al.
Publicado: (2022)

Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Gager, Gloria M., et al.
Publicado: (2021)

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
por: Liang, Bo, et al.
Publicado: (2022)

Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcome and safety events: A meta-analysis of randomized controlled clinical trials
por: Gong, Chen, et al.
Publicado: (2022)

Potential favorable action of sodium-glucose cotransporter-2 inhibitors on sudden cardiac death: a brief overview
por: Sato, Tatsuya, et al.
Publicado: (2023)

Commentary: Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Qiu, Mei, et al.
Publicado: (2021)

Association between the neutrophil-to-lymphocyte ratio and risk of in-hospital heart failure and arrhythmia in patients with acute myocardial infarction
por: Zhang, Jia-li, et al.
Publicado: (2023)

Effect of sacubitril/valsartan on the occurrence of cardiac arrhythmias and the risk of sudden cardiac death in heart failure: A meta-analysis of randomized controlled trials
por: Liu, Xue-Hui, et al.
Publicado: (2022)

Role of the Gut Microbiota in Glucose Metabolism During Heart Failure
por: Bao, Pei, et al.
Publicado: (2022)

Sodium–glucose cotransporter-2 inhibitor alleviated atrial remodeling in STZ-induced diabetic rats by targeting TLR4 pathway
por: Zhan, Xiaoping, et al.
Publicado: (2022)

Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
por: Joshi, Shruti S, et al.
Publicado: (2021)

Eligibility of outpatients with chronic heart failure for sodium–glucose co‐transporter‐2 inhibitors
por: Angelini, Gianmarco, et al.
Publicado: (2021)

Triglyceride-glucose index for the detection of subclinical heart failure with preserved ejection fraction in patients with type 2 diabetes
por: Wang, Tingting, et al.
Publicado: (2023)

Renal and Cardiovascular Effects of sodium–glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial
por: Mordi, Natalie A, et al.
Publicado: (2017)

SGLT2 Inhibitors Play a Salutary Role in Heart Failure via Modulation of the Mitochondrial Function
por: Maejima, Yasuhiro
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tfqoaan25eblosnuu6ujq0bdc6